Abbott Laboratories (ABT) investor relations material

Executive summary

• Q2 2026 worldwide sales reached $12.6B, up 13.0% reported and 14.8% comparable in some disclosures, with adjusted EPS of $1.312, exceeding guidance midpoint and consensus.

• Full-year comparable sales growth guidance reaffirmed at 6.5%-7.5%, and adjusted EPS guidance raised to $5.45-$5.60.

• Key business units posted strong sales: Medical Devices $5.9B, Diagnostics $3.1B, Nutrition $2.1B, Established Pharmaceuticals $1.5B.

• Multiple product launches, clinical trial initiations, and pipeline investments are planned over the next 12 months.

• $2.1B returned to shareholders via dividends and share repurchases in Q2.

Financial highlights

• Adjusted gross margin improved to 58.0% of sales, up 100 basis points year-over-year.

• Q2 2026 net sales: $12.6B (+13.0% reported, +4.8% comparable); adjusted diluted EPS: $1.31 (+4.0% year-over-year).

• Operating earnings: $1.69B; adjusted net earnings: $2.29B (+3.5%).

• Q3 adjusted EPS forecasted at $1.38-$1.46.

• Gross margin (adjusted): $7.31B in Q2 2026.

Outlook and guidance

• Full-year comparable sales growth guidance maintained at 6.5%-7.5%.

• Full-year adjusted EPS guidance raised to $5.45-$5.60.

• Third quarter adjusted EPS expected between $1.38 and $1.46.

• Key growth acceleration in H2 expected from nutrition, electrophysiology, core lab, and cancer diagnostics.